Autologous transplantation of bone marrow mononuclear stem cells by mini-thoracotomy in dilated cardiomyopathy: technique and early results
Renato Abdala Karam Kalil, Daniele Ott, Roberto Sant'Anna, Eduardo Dias, João Pedro Marques-Pereira, Andrés Delgado-Cañedo, Nance Beyer Nardi, João Ricardo Michelin Sant'Anna, Paulo Roberto Prates, Ivo Nesralla, Renato Abdala Karam Kalil, Daniele Ott, Roberto Sant'Anna, Eduardo Dias, João Pedro Marques-Pereira, Andrés Delgado-Cañedo, Nance Beyer Nardi, João Ricardo Michelin Sant'Anna, Paulo Roberto Prates, Ivo Nesralla
Abstract
Context and objectives: There are few studies concerning bone marrow mononuclear cell (BMMC) transplantation in cases of nonischemic dilated cardiomyopathy. This study describes a novel technique of BMMC transplantation and the results up to one year after the procedure.
Design and setting: This was a case series to evaluate the safety and viability of the procedure, at Instituto de Cardiologia do Rio Grande do Sul.
Methods: Nine patients with symptomatic dilated cardiomyopathy, functional class III/IV and left ventricular ejection fraction (LVEF) < 35% received BMMC (9.6 +/- 2.6 x 107 cells) at 20 sites in the ventricular wall, by means of thoracotomy of length 5 cm in the fifth left intercostal space. Echocardiograms and nuclear magnetic resonance (NMR) were performed.
Results: There were no major complications. The functional class results for the first six patients (preoperatively and at two, four, eight and twelve-month follow-ups, respectively) were: [IV-2, III-4] to [I-5, II-1] to [I-3, II-3] to [I-2, II-3] and [I-2, II-3]. Echocardiograms showed LVEF: 25.9 +/- 8.2; 32.9 +/- 10.4; 29.4 +/- 7.2; 25.1 +/- 7.9; 25.4 +/- 6.8% (p = 0.023); and % left ventricular (LV) fiber shortening: 12.6 +/- 4.4; 16.4 +/- 5.4; 14.3 +/- 3.7; 12.1 +/- 4.0; 12.2 +/- 3.4% (p = 0.021). LV performance variation seen on NMR was non-significant.
Conclusion: Intramyocardial transplantation of BMMC in dilated cardiomyopathy cases is feasible and safe. There were early improvements in symptoms and LV performance. Medium-term evaluation revealed regression of LV function, although maintaining improved functional class.
Trial registration: ClinicalTrials.gov NCT00615394.
Source: PubMed